Medicus Pharma Proposes $135M SkinJect SPAC Combination

Medicus Pharma’s subsidiary SkinJect signed a non-binding LOI with an undisclosed SPAC for a proposed combination at a $135M pre-money enterprise valuation, with concurrent equity financing. Medicus seeks to retain majority ownership; completion is anticipated in the first half of 2027, subject to…